Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Amrubicin Chemotherapy as First Line Treatment in Patients With Metastatic or Unresectable Soft Tissue Sarcoma

NCT01259375 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT01259375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01259375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Amrubicin Chemotherapy as First Line Treatment in Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
February 29, 2016
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma